UVA Islet Cell Transplantation in Patients With Type I Diabetes

NCT00605592

Last updated date
Study Location
University of Virginia
Charlottesville, Virginia, 22908, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 1 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Type I Diabetes Mellitus for at least 5 years

- Unstable control of diabetes despite intensive care by an endocrinologist, including episodes of dangerously low blood sugars

- Group I must have healthy kidneys

- Group II (islet after kidney) must have a stable kidney allograft for at least 6 months

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Unstable diabetic eye disease


- Poor kidney function


- Type II Diabetes as determined by blood tests


- Any history of cancer, except certain skin cancers


- Pregnant or unwilling to use adequate birth control


- Very high hemoglobin A1c levels


- Poor control of blood pressure, despite use of medications


- Very high insulin requirements


- History of exposure to HIV


- Active Hepatitis B or Hepatitis C infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Type 1 Diabetes MellitusStudy to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes
NCT00315952
  1. Pittsburgh, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 1 Diabetes MellitusUVA Islet Cell Transplantation in Patients With Type I Diabetes
NCT00605592
  1. Charlottesville, Virginia
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 1 Diabetes MellitusPositron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients
NCT00958997
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 1 Diabetes MellitusSafety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
NCT00479258
  1. Buffalo, New York
ALL GENDERS
6 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE UVA Islet Cell Transplantation in Patients With Type I Diabetes
Official Title  ICMJE UVA Islet Cell Transplantation in Patients With Type I Diabetes
Brief Summary

This protocol will provide islet cell transplantation to two separate populations in need of a pancreas transplant:

Group I: Islet Cell Transplantation in Type I Diabetics without Kidney Problems

Group II: Islet Cell Transplantation in Type I Diabetics Who Have a Stable Functioning Kidney Transplant

The targeted patients have very brittle diabetes or dangerous hypoglycemic unawareness and may benefit from transplantation over continuing insulin therapy, even though chronic immunosuppression is required. We believe that in these patients, the islet transplant procedure promises enough potential benefit to justify subjecting patients who have not previously had a transplant to the risk of immunosuppression.

In patients who are already subject to the dangers of chronic immunosuppression for other reasons, i.e. to prevent rejection of a kidney allograft, the islet transplantation procedure itself is the principal additional risk and this risk should be minimal. In these patients (our Group II), the potential benefit from improved glycemic control is that it promises to slow or even reverse diabetic complications, such as vascular problems leading to kidney damage. It is this rationale that has made pancreas transplantation a widely accepted option in patients with renal failure, despite the risks associated with whole pancreas transplantation. Islet cell transplantation aims to provide a potentially lower risk procedure that has similar relief from diabetic complications.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Diabetes Mellitus, Type 1
Intervention  ICMJE Procedure: Pancreatic Islets of Langerhans Cell Transplant
Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
Other Names:
  • Islet Cell Transplant
  • Pancreatic Islet Cell Transplantation
Study Arms  ICMJE Experimental: 1
Islet cell transplant
Intervention: Procedure: Pancreatic Islets of Langerhans Cell Transplant
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: January 30, 2008)
20
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 2012
Estimated Primary Completion Date January 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Type I Diabetes Mellitus for at least 5 years
  • Unstable control of diabetes despite intensive care by an endocrinologist, including episodes of dangerously low blood sugars
  • Group I must have healthy kidneys
  • Group II (islet after kidney) must have a stable kidney allograft for at least 6 months

Exclusion Criteria:

  • Unstable diabetic eye disease
  • Poor kidney function
  • Type II Diabetes as determined by blood tests
  • Any history of cancer, except certain skin cancers
  • Pregnant or unwilling to use adequate birth control
  • Very high hemoglobin A1c levels
  • Poor control of blood pressure, despite use of medications
  • Very high insulin requirements
  • History of exposure to HIV
  • Active Hepatitis B or Hepatitis C infection
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00605592
Other Study ID Numbers  ICMJE 12839
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Kenneth Brayman/MD, PhD, University of Virginia
Study Sponsor  ICMJE University of Virginia
Collaborators  ICMJE
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Wyeth is now a wholly owned subsidiary of Pfizer
Investigators  ICMJE
Principal Investigator:Kenneth Brayman, MD, PhDUniversity of Virginia
PRS Account University of Virginia
Verification Date February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP